We are live on ! Find out more
RJA

Raymond James & Associates Portfolio holdings

AUM $164B
1-Year Est. Return 33.91%
This Fund
S&P 500
This Quarter Est. Return
+1.61%
1 Year Est. Return
+33.91%
3 Year Est. Return
+39.99%
5 Year Est. Return
+107.66%
10 Year Est. Return
+436.07%
AUM
$71.7B
AUM Growth
+$2.34B
Cap. Flow
+$1.49B
Cap. Flow %
2.08%
Top 10 Hldgs %
21.97%
Holding
3,809
New
183
Increased
1,708
Reduced
1,572
Closed
206

Sector Composition

Rank Sector Weight
1 Technology 10.59%
2 Financials 9.51%
3 Healthcare 8.04%
4 Industrials 6.62%
5 Communication Services 5.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
NXRT
2451
NexPoint Residential Trust
NXRT
$631M
$654K ﹤0.01%
13,994
-2,194
-14% -$98.1K
SMPL icon
2452
Simply Good Foods
SMPL
$961M
$652K ﹤0.01%
22,501
+6,708
+42% +$187K
FCFS icon
2453
FirstCash
FCFS
$9.04B
$649K ﹤0.01%
7,080
+784
+12% +$77.8K
CNXM
2454
DELISTED
CNX Midstream Partners LP
CNXM
$649K ﹤0.01%
46,053
+6,913
+18% +$99.4K
FULT icon
2455
Fulton Financial
FULT
$4.65B
$647K ﹤0.01%
39,981
+1,047
+3% +$17K
JBLU icon
2456
JetBlue
JBLU
$2.19B
$646K ﹤0.01%
38,582
-44,341
-53% -$804K
PSK icon
2457
State Street SPDR ICE Preferred Securities ETF
PSK
$683M
$646K ﹤0.01%
14,620
-2,016
-12% -$88.2K
MFIC icon
2458
MidCap Financial Investment
MFIC
$804M
$645K ﹤0.01%
40,089
-9,892
-20% -$162K
APLE icon
2459
Apple Hospitality REIT
APLE
$3.68B
$644K ﹤0.01%
38,849
-1,739
-4% -$27.5K
BPMC
2460
DELISTED
Blueprint Medicines
BPMC
$644K ﹤0.01%
8,768
+741
+9% +$64.1K
FMN
2461
Federated Hermes Premier Municipal Income Fund
FMN
$87.1M
$642K ﹤0.01%
45,275
-2,000
-4% -$27.9K
CHI
2462
Calamos Convertible Opportunities and Income Fund
CHI
$1.06B
$641K ﹤0.01%
61,579
+88
+0.1% +$928
FN icon
2463
Fabrinet
FN
$18.8B
$641K ﹤0.01%
+12,248
New +$642K
CCLP
2464
DELISTED
CSI Compressco LP
CCLP
$641K ﹤0.01%
216,689
-5,772
-3% -$18.8K
CMD
2465
DELISTED
Cantel Medical Corporation
CMD
$640K ﹤0.01%
8,558
+4,707
+122% +$399K
SRLP
2466
DELISTED
SPRAGUE RESOURCES LP
SRLP
$639K ﹤0.01%
36,116
-2,400
-6% -$41.7K
GRPN icon
2467
Groupon
GRPN
$889M
$637K ﹤0.01%
11,969
-364
-3% -$21.4K
CABO icon
2468
Cable One
CABO
$192M
$634K ﹤0.01%
505
+17
+3% +$21.1K
CVI icon
2469
CVR Energy
CVI
$3.42B
$634K ﹤0.01%
14,406
+2,736
+23% +$127K
MCHX icon
2470
Marchex
MCHX
$77.1M
$634K ﹤0.01%
201,782
+691
+0.3% +$2.66K
I
2471
DELISTED
INTELSAT S. A.
I
$634K ﹤0.01%
+27,788
New +$586K
DIV icon
2472
Global X SuperDividend US ETF
DIV
$773M
$633K ﹤0.01%
26,844
-386
-1% -$8.82K
SLGN icon
2473
Silgan Holdings
SLGN
$4.35B
$633K ﹤0.01%
21,090
-3,354
-14% -$101K
CUT icon
2474
Invesco MSCI Global Timber ETF
CUT
$33.6M
$632K ﹤0.01%
24,294
+2,843
+13% +$73.3K
DRRX
2475
DELISTED
DURECT Corp
DRRX
$631K ﹤0.01%
34,300
-2,000
-6% -$27K

Similar funds

Raymond James & Associates's Q3 2019 Portfolio in Review

As of Q3 2019, Raymond James & Associates held 3,809 positions worth $71.7B, up 3.4% from $69.4B the previous quarter. Its ten largest holdings account for 22% of the portfolio.

Raymond James & Associates's Q3 2019 filing shows 183 new, 1,708 increased, 1,572 reduced and 206 closed positions. Its largest new stake was Change Healthcare Inc. Common Stock: 949,970 shares worth $11.5M. The largest sale was Microchip Technology, an estimated $155M.

By sector, the portfolio is most concentrated in Technology at 11% of assets, up from 11% a quarter earlier, followed by Financials and Healthcare.

  • Raymond James & Associates's largest Q3 2019 buy was Change Healthcare Inc. Common Stock: 949,970 shares worth $11.5M.
  • Raymond James & Associates added most to Comcast in Q3 2019, an estimated $203M increase.
  • Raymond James & Associates's biggest Q3 2019 reduction was Microchip Technology, cutting an estimated $155M.
  • Raymond James & Associates fully exited Anadarko Petroleum in Q3 2019, selling an estimated $89.3M.
  • Raymond James & Associates's ten largest holdings make up 22% of its $71.7B portfolio in Q3 2019.
  • Raymond James & Associates opened 183 new positions and closed 206 in Q3 2019.
  • Raymond James & Associates's portfolio value rose 3.4% quarter-over-quarter to $71.7B.

Based on Raymond James & Associates's 13F filing for Q3 2019, filed 7 Nov 2019.